Passage Bio
PASG
45 hedge funds and large institutions have $458M invested in Passage Bio in 2020 Q1 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.31% more ownership
Funds ownership: 0% → 3.31% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$109M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$78.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$49M |
| 4 |
NLVP
New Leaf Venture Partners
New York
|
+$39.1M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$34.9M |
Top Sellers
PASG Hedge Fund Activity: Q1 2020 in Review
45 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q1 2020, worth a combined $458M.
Buyers outnumbered sellers: 45 funds opened new PASG positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $109M.
- 45 institutional investors held Passage Bio (PASG) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $458M of Passage Bio stock for Q1 2020.
- 45 funds opened new Passage Bio positions in Q1 2020 and 0 closed out, a net change of +45 holders.
- The largest Passage Bio buyer in Q1 2020 was OrbiMed, an estimated $109M added.
Based on aggregated 13F filings for Q1 2020.